spinnerspinball| Kanglon Chemical Corporation and AstraZeneca China reached strategic cooperation and added an investment of 91 million yuan

May 20spinnerspinball, domestic cXO company Kanglong Chemical Corporation (300759) announced that it will cooperate with AstraZeneca China on R & D and commercialization throughout the entire process of drug discovery, preclinical and clinical development, including small molecule, macromolecule, cell and gene therapy drugs. Comprehensive strategic cooperation has been reached with integrated production services and investment in innovative drug research and development. At the same time, KangLoong Chemical Corporation plans to invest an additional 91 million yuan in Wuxi AstraZeneca CICC Venture Capital Fund.

The 2023 annual report shows that Kanglon Chemical Corporation's revenue is 115spinnerspinball.38 billion yuan, a year-on-year increase of 12spinnerspinball.39%, and the net profit attributable to the parent company was 1.601 billion yuan, a year-on-year increase of 16.48%. According to the first quarter 2024 results announcement, the company's first quarter revenue was approximately 2.671 billion yuan, a year-on-year decrease of 1.95%spinnerspinball; Net profit attributable to shareholders of listed companies was approximately 231 million yuan, a year-on-year decrease of 33.8%.